Cellafa Bioscience
About
Cellafa Bioscience is a next-generation cell therapy CDMO with a strong focus on iPSC‑derived cell therapies, supporting process development, scale-up, and GMP manufacturing from early-stage development.
Founded as a joint venture between Astellas Pharma and Yaskawa Electric, Cellafa uniquely combines pharmaceutical-grade CMC expertise with robotics and automation. Our manufacturing platform leverages a robotic cell culture system that has received an FDA Advanced Manufacturing Technology (AMT) designation, underscoring its ability to enhance manufacturing robustness, reproducibility, and product quality.
By embedding, comprehensive data capture, and AI-driven analysis from early development stages, we help partners improve process robustness, ensure consistent product quality, and accelerate development timelines.
Cellafa partners with biotech companies as a long-term development and manufacturing partner, enabling the industrialization of next-generation cell therapies.
Areas of activity
Business Domain / 分野
Disease Area / 疾患領域
Technologies / 技術
Business Type / 業種
Modalities / モダリティ
Additional information
企業/団体名 (日本語) / Company name in Japanese
セラファ・バイオサイエンス
Researched company/organisation type / マッチングご希望企業・機関のタイプ
Researched disease area / マッチングご希望の疾患領域
Researched Modality / マッチングご希望のモダリティ
Researched Technologies / マッチングご希望の技術